IRAK2, short for interleukin-1 receptor-associated kinase 2, is a signaling protein that sits near the top of one of the immune system’s most important alarm chains. When cells detect bacterial, viral, or fungal invaders through their Toll-like receptors, IRAK2 helps relay that danger signal inward, ultimately switching on genes that produce inflammation and recruit other immune cells. Research over the past decade has revealed that IRAK2 does more than simply pass a message along: it shapes how strong the inflammatory response is, how long it lasts, and whether certain disease-promoting genes get turned on or stay quiet. Disruptions in IRAK2 have now been linked to autoimmune conditions, severe infections, cancer progression, and a gastrointestinal inflammatory disorder that resembles Crohn’s disease.
How IRAK2 Fits Into the Immune Alarm Chain
Your immune cells are studded with pattern-recognition sensors called Toll-like receptors (TLRs). When a TLR locks onto a piece of a pathogen, it triggers an internal signaling cascade that begins with an adaptor protein called MyD88. MyD88 acts as a scaffold, pulling together a multi-protein complex known as the Myddosome. The IRAK family of kinases, including IRAK1, IRAK2, and IRAK4, are the core players recruited into this complex.1PubMed Central. Regulation of innate immune signaling by IRAK proteins Once assembled, the Myddosome activates downstream pathways that lead to the production of inflammatory molecules called cytokines, which coordinate the body’s fight against infection.
IRAK2’s specific job within the Myddosome centers on its physical interaction with IRAK4. The contact surface between the two proteins is substantial. Structural analysis shows that a stretch of amino acids near IRAK2’s front end accounts for nearly all of its binding area with IRAK4.2Nature Communications. IRAK2 deficiency causes immune dysregulation through defective Myddosome assembly and enhanced interferon responses Delete that stretch, and IRAK2 can no longer grab onto IRAK4, even though it can still bind other partners like TRAF6, a protein further down the chain. This means IRAK2’s role is not redundant with IRAK4’s; it occupies a distinct structural position in the complex that no other family member fills in quite the same way.
Beyond Flipping a Switch: IRAK2 and Post-Transcriptional Control
One of IRAK2’s more surprising functions involves what happens after genes are already switched on. When a macrophage is stimulated by bacterial components like lipopolysaccharide (LPS), the initial burst of gene activation is only part of the story. Many inflammatory messenger molecules are produced from unstable RNA transcripts that are quickly broken down unless something stabilizes them. IRAK2 helps keep those RNA transcripts intact long enough for the cell to translate them into functional proteins.
Experiments in IRAK2-deficient macrophages showed that the activation of a signaling branch involving MAP kinases was reduced after LPS stimulation. A downstream protein called tristetraprolin (TTP), which normally degrades inflammatory RNA transcripts, failed to accumulate properly in cells lacking IRAK2. The result was that the cell’s inflammatory output dropped, not because the initial alarm was never sounded but because the message faded before it could be fully acted on.3Journal of Biological Chemistry. Interleukin-1 Receptor-associated Kinase 2 Is Critical for Lipopolysaccharide-mediated Post-transcriptional Control This post-transcriptional role makes IRAK2 unusual among IRAK family members: it is not just a relay station but also a volume knob for the inflammatory response.
What Happens When IRAK2 Is Missing or Broken
Until recently, no one had documented a human disease caused by loss-of-function mutations in IRAK2. That changed with the identification of patients carrying a specific deletion that removes a critical exon from the IRAK2 gene. The resulting truncated protein can no longer bind IRAK4, and the Myddosome fails to assemble properly. The downstream consequence is impaired activation of NF-ĪŗB, the master transcription factor for inflammatory genes.4PubMed Central. IRAK2 deficiency causes immune dysregulation through defective Myddosome assembly and enhanced interferon responses
Macrophages derived from mice carrying this mutation showed signaling defects across a wide array of TLR pathways, including those activated by LPS (TLR4), viral RNA mimics (TLR7/8), bacterial lipoproteins (TLR2/TLR6 and TLR1/TLR2), and synthetic DNA sequences (TLR9). One pathway stood out as unaffected: TLR3, which does not use MyD88 and instead relies on a different adaptor protein called TRIF.5Nature Communications. IRAK2 deficiency causes immune dysregulation through defective Myddosome assembly and enhanced interferon responses – Section: Results The selective sparing of TLR3 reinforces IRAK2’s specific role in MyD88-dependent signaling.
In affected patients, the clinical picture was striking. Two individuals primarily developed gastrointestinal disease, with abdominal pain, vomiting, and bloody stools. Endoscopy revealed ulcers throughout the digestive tract, and tissue samples showed hallmarks of severe intestinal inflammation, including crypt abscesses in the ileocecal region.6Nature Communications. IRAK2 deficiency causes immune dysregulation through defective Myddosome assembly and enhanced interferon responses – Section: Mutation in IRAK2 defines an immune dysregulation disorder The resemblance to inflammatory bowel disease is notable, and it suggests that IRAK2 is required not only for fighting off pathogens but also for maintaining immune balance in the gut.
IRAK2 and Vulnerability to Severe Infections
A separate line of evidence ties IRAK2 mutations to dangerous susceptibility to a wide range of infections. In two patients who experienced sequential or repeated invasive infections, including herpes simplex virus-triggered hemophagocytic lymphohistiocytosis (a runaway immune activation syndrome) combined with tuberculosis in one case and bacterial bloodstream infection with a fungal co-infection in the other, novel IRAK2 mutations were identified. These mutations specifically impaired the ability of IRAK2 to modify its downstream partner TRAF6 through a process called ubiquitination, which in turn reduced the production of the cytokine tumor necrosis factor-alpha (TNF-Ī±).7PubMed. Severe invasive infections linked to IRAK2 immune variants
The breadth of pathogens involved, a virus, a mycobacterium, a bacterium, and a fungus, is telling. It suggests that IRAK2 sits at a point in the immune network that is general-purpose rather than specialized for one type of threat. Lose it, and the body’s defenses weaken against almost everything that TLR signaling is supposed to detect. This makes IRAK2 deficiency fundamentally different from many other genetic immune disorders, which tend to create vulnerability to a narrower category of infection.
Autoimmune Disease Connections
While loss of IRAK2 weakens certain immune responses, having particular IRAK2 gene variants may push the system in the opposite direction, toward overactivity and autoimmunity. Genetic studies have found associations between specific IRAK2 single-nucleotide polymorphisms (common single-letter variations in the DNA sequence) and susceptibility to both rheumatoid arthritis and systemic lupus erythematosus.
For rheumatoid arthritis, a variant at the IRAK2 rs3844283 position was found to roughly double the odds of disease in individuals carrying two copies of the risk allele. Another variant at rs708035 was also more common in patients than in healthy controls.8PubMed. IRAK2 is associated with susceptibility to rheumatoid arthritis A subsequent study in a different population replicated the involvement of both variants, identifying both protective and risk-associated combinations and proposing that IRAK2 variants could serve as biomarkers for diagnostic purposes and precision medicine approaches.9PubMed Central. Multi-locus SNP analyses of interleukin 1 receptor associated kinases 2 gene polymorphisms with the susceptibility to rheumatoid arthritis
For lupus, the same two IRAK2 variants and their corresponding haplotypes were associated with disease risk, representing the first report of IRAK2’s involvement in lupus susceptibility.10PubMed. IRAK2 is associated with systemic lupus erythematosus risk The fact that the same variants appear relevant across two different autoimmune conditions reinforces the idea that IRAK2 sits at a shared inflammatory bottleneck. Tweak its activity up or down, and the consequences ripple outward.
IRAK2 in Cancer
Chronic inflammation and cancer are intertwined, so it is not entirely surprising that IRAK2 has turned up in tumor biology. In pancreatic ductal adenocarcinoma (PDAC), one of the most lethal solid cancers, IRAK2 is highly expressed in patient tumor samples and is associated with a worse prognosis. Experimentally knocking down IRAK2 in pancreatic cancer cells slowed their growth, partly by disrupting a metabolic shift known as the Warburg effect, in which cancer cells ramp up sugar consumption even when oxygen is plentiful. The mechanism traced back to NF-ĪŗB, the same transcription factor that IRAK2 activates in normal immune signaling, which in the cancer context helps sustain tumor growth.11PubMed Central. IRAK2-NF-ĪŗB signaling promotes glycolysis-dependent tumor growth in pancreatic cancer
IRAK2’s relationship with cancer is not one-size-fits-all, though. A pan-cancer analysis that surveyed IRAK2 expression across dozens of tumor types found that high IRAK2 levels predicted worse outcomes in glioblastoma, lung adenocarcinoma, liver cancer, and several others. But in bladder cancer, breast cancer, kidney cancer, and melanoma, higher IRAK2 expression was actually associated with better survival.12PubMed Central. Comprehensive pan-cancer characterization of IRAK2 as a potential prognostic biomarker and therapeutic target with validation in hepatocellular carcinoma The likely explanation is that IRAK2’s effect depends on the tumor’s immune microenvironment: in some cancers, the inflammation IRAK2 promotes fuels tumor growth, while in others, it helps immune cells recognize and attack the tumor. This split makes clinical translation tricky, because simply blocking IRAK2 everywhere could harm patients with cancers where its activity is protective.
Why Mouse Studies Do Not Always Predict Human IRAK2 Biology
A significant complication for IRAK2 research is that the protein does not behave identically in mice and humans. Mouse and human IRAK2 share only about 67% of their amino acid sequence. The mouse version has a longer tail at one end and, critically, does not boost NF-ĪŗB activation in the way the human version does.13PubMed. Identification and characterization of murine IRAK-2
A comprehensive comparison of TLR signaling in human and mouse macrophages made the divergence even clearer. In mouse macrophages, TLR signaling depended heavily on IRAK4 and IRAK2, with IRAK1 playing little or no role. In human macrophages, the hierarchy flipped: IRAK1 was the main player, and knocking down IRAK4 or IRAK2 had a smaller effect on cytokine production. The species differences were so pronounced that mouse IRAK4 could not substitute for human IRAK4 in rescue experiments, and vice versa.14PubMed Central. Comprehensive RNAi-based screening of human and mouse TLR pathways identifies species-specific preferences in signaling protein use
This matters because the vast majority of mechanistic studies on IRAK2 have been done in mouse cells. Findings from those studies may overstate or understate IRAK2’s importance in human disease, depending on the context. Human clinical observations, like those from the patients with IRAK2 mutations described earlier, are therefore especially valuable for grounding the field’s understanding.
How the Body Keeps IRAK2 in Check
Because too much IRAK2 activity can drive harmful inflammation, the body has evolved mechanisms to rein the protein in. One recently characterized pathway involves an E3 ubiquitin ligase called Pellino-1, or PELI1. In airway epithelial cells, overexpression of PELI1 tagged IRAK2 with a specific type of ubiquitin chain (K63-linked), marking it for degradation and shortening its lifespan inside the cell. In the absence of PELI1, such as when cells were exposed to house dust mite allergen, the ubiquitination of IRAK2 dropped and the protein accumulated, contributing to airway inflammation.15American Journal of Respiratory Cell and Molecular Biology. IRAK2 ubiquitination mediated by PELI1 regulates airway epithelial function and alleviates pediatric asthma
This degradation mechanism has practical implications for understanding asthma. If the cell’s disposal system for IRAK2 falters during allergen exposure, excess IRAK2 could amplify inflammation in the airways. Restoring or mimicking PELI1 activity might, in theory, bring IRAK2 levels back to normal and ease inflammatory symptoms. The finding also illustrates a general principle: the immune system does not just regulate whether a gene is turned on or off. It fine-tunes the amount of active protein sitting in the cell at any given moment.
Therapeutic Approaches Targeting IRAK2
The evidence linking IRAK2 to autoimmunity, cancer, infection susceptibility, and asthma has naturally prompted interest in therapeutic strategies aimed at this protein. One approach that has reached the proof-of-concept stage involves small molecules designed to mimic part of IRAK2’s structure and block it from joining the Myddosome.
Researchers synthesized compounds modeled on a coil-shaped segment of IRAK2 that normally contacts IRAK4. These molecules wedge themselves into the IRAK2-IRAK4 interface, preventing the Myddosome from forming. In cell-based assays, the lead compound suppressed NF-ĪŗB activity driven by the inflammatory cytokine IL-33. When tested in mouse models of asthma, the compound reduced airway inflammation triggered by both IL-33 and ovalbumin (a common allergen used in lab models).16The Journal of Immunology. Small Molecule Mimetics of Ī±-Helical Domain of IRAK2 Attenuate the Proinflammatory Effects of IL-33 in Asthma-like Mouse Models
Separately, the broader IRAK family has attracted attention as a drug target in the context of SARS-CoV-2-related cytokine storm, the dangerous over-activation of the immune system seen in severe COVID-19. Because the TLR/IL-1R signaling pathway that IRAK proteins mediate is central to the production of inflammatory cytokines, dampening IRAK activity was proposed as a strategy for calming the runaway inflammation.17SpringerLink. Modulation of IRAK enzymes as a therapeutic strategy against SARS-CoV-2 induced cytokine storm No IRAK2-specific drug has entered clinical trials as of mid-2025, but the approach is being explored alongside broader IRAK4 inhibitors that are further along in development for blood cancers and autoimmune diseases.
IRAK2 Expression Changes During Cell Maturation
IRAK2 levels are not fixed throughout a cell’s life. When immature blood cells differentiate into macrophages, the process itself appears to upregulate IRAK2 expression, amplifying the cell’s readiness to respond to threats. In one study, a human myeloid leukemia cell line (ML-1) was treated with a compound that drives differentiation toward a macrophage-like state. Along with increased expression of TLR1, TLR2, and TLR4, the cells also ramped up their IRAK2 gene expression. The combined effect was a heightened sensitivity to bacterial components like LPS and lipoteichoic acid.18PubMed Central. Upregulation of TLR1, TLR2, TLR4, and IRAK-2 Expression During ML-1 Cell Differentiation to Macrophages: Role in the Potentiation of Cellular Responses to LPS and LTA
This co-upregulation makes biological sense. A newly minted macrophage arriving in tissue needs both the receptors to detect pathogens and the internal signaling machinery to act on that detection. IRAK2 is part of that coordinated ramp-up. It also hints at why certain immune deficiencies caused by IRAK2 mutations are so broad in their consequences: if IRAK2 is required for the full functional maturation of macrophage signaling, a broken version would leave these frontline immune cells partially blind even when their sensors are intact.
Evolutionary History of the IRAK Family
IRAK2 belongs to a kinase family that evolved by duplication and divergence from a single ancestral gene. Phylogenetic analysis suggests that all four IRAK proteins, IRAK1 through IRAK4, diverged from an IRAK4-like ancestor early in animal evolution. Over time, the family members acquired distinct enzymatic properties. IRAK1 and IRAK4 retained robust kinase activity, meaning they can add phosphate groups to target proteins. IRAK2, by contrast, is classified as a “non-RD kinase” because of a change in a key amino acid in its catalytic domain: where active kinases have an arginine, IRAK2 has a serine. This substitution effectively silences its kinase function.19PLOS ONE. Molecular Evolution and Structural Features of IRAK Family Members
The fact that IRAK2 persists in the genome despite having lost enzymatic punch tells us something about its value. Its importance lies not in what it catalyzes but in what it organizes: assembling the Myddosome, stabilizing RNA transcripts, and serving as a scaffold for other proteins to interact. In evolutionary terms, IRAK2 shifted from being a worker enzyme to being a structural coordinator, and that shift made it indispensable in its own right.